The impact of enzalutamide on the prostate cancer patient experience: a summary review of health-related quality of life across pivotal clinical trials

Bertrand Tombal, Arnulf Stenzl, David Cella, Yohann Loriot, Andrew J. Armstrong, Karim Fizazi, Tomasz Beer, Cora N. Sternberg, Maha Hussain, Cristina Ivanescu, Arijit Ganguli*, Krishnan Ramaswamy, Fred Saad

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

This review examines the impact of treatment with enzalutamide on health-related quality of life (HRQoL) in prostate cancer patients across the disease continuum based on pivotal clinical trials. We assessed the effect of enzalutamide on pain, symptom burden and overall HRQoL from randomized controlled trials. Patient experience was evaluated in men with metastatic hormone-sensitive prostate cancer (mHSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) (pre-chemotherapy and post-chemotherapy). Patients across the disease continuum reported a generally positive status at baseline, with relatively low levels of pain and impairment due to cancer-related symptoms and high HRQoL. For patients with earlier-state prostate cancer, pain and symptom-related burden were low at study entry and remained so, regardless of whether patients received enzalutamide or control treatment. Patients with more advanced disease reported mitigation in pain and symptom burden while receiving treatment with enzalutamide. Enzalutamide was observed to slow deterioration of overall HRQoL most for patients with nmCRPC or mCRPC (statistical significance for between-group difference in median time to deterioration: mHSPC (confirmed) p = 0.2998; nmCRPC (confirmed) p = 0.0044; mCRPC (unconfirmed) p < 0.0001). Across the prostate cancer continuum, enzalutamide is well-tolerated and delays the negative impact that disease progression has on quality of life.

Original languageEnglish (US)
Article number5872
JournalCancers
Volume13
Issue number23
DOIs
StatePublished - Dec 2021

Keywords

  • Anti-neoplastic agents
  • Cancer pain
  • Prostatic neoplasms
  • Quality of life
  • Treatment outcome

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The impact of enzalutamide on the prostate cancer patient experience: a summary review of health-related quality of life across pivotal clinical trials'. Together they form a unique fingerprint.

Cite this